Potentially. But we'd need a better idea of how much of a buffer they have given themselves. As you know, clinical trials always take longer than expected and cost significantly more than planned. But either way, they have demonstrated that they are financially savvy and don't waste money. If any biotech is going to be in time and under budget, it'll be IXC
Potentially. But we'd need a better idea of how much of a buffer...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.763M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 41290 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.9¢ | 59180 | 2 |
View Market Depth
| Last trade - 16.21pm 11/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable